About Us

Whether you are an investor seeking to support groundbreaking medical solutions or a channel or technology partner ready to collaborate on cutting-edge projects, we warmly welcome you to join us in driving the future of biomedical innovation.

Management

Chairman Huang leads Jim Brother’s Corp., Fixwell Technology Corp., and Blue Blood Biotech Corp. as Chairman, bringing seasoned management expertise across multiple sectors, including biotech, semiconductors, manufacturing, and finance. His professional foundation was built at industry-leading telecommunications and semiconductor firms, including WNC Corporation and King Yuan Electronics Co., Ltd..

He earned his B.S. in Computer Science from Tunghai University and holds an MBA from Concordia University, Canada.

Dr. Lin is a biomedical scientist with over 20 years of commercial process in life science industries, including medical devices, pharmaceutical, biomaterials manipulate technology and biochips.
Prior to joining Blue Blood Biotech Corp., Dr. Lin was the Deputy Project Director of Industrial Technology.

Harry Su, Vice President, has more than 18 years of experience in the capital markets. His areas of expertise include capital markets, financial management, and capital planning. He has worked at Yuanta Securities, Taishin Securities, and CTBC Securities, where he assisted numerous companies in accessing the capital markets and raising funds. He possesses extensive experience in planning IPO and OTC listings as well as regulatory compliance. He has also served at Taya Group and Etron Technology, supporting companies in formulating business strategies and mitigating corporate risks, with diversified industry experience.

Innovation Team

Dr. Ding holds a Ph.D. in Microbiology from National Chung Hsing University, with a focus on Bacteriology, Bioinformatics, and Molecular Biotechnology. With over 10 years of research experience in microbial genomics, microbial ecology, and related fields, Dr. Ding has an extensive background in advanced microbiological studies.
Dr. Ding oversees product development and market analysis with more than three years of experience in this role. Leveraging expertise in microbiology, Dr. Ding also leads the integration of AI-driven technologies to optimize recombinant protein production.

Advisory Board

Dr. Wu is a professor of Department of Biochemistry and Molecular Biology, College of Medicine, National Cheng Kung University. Wu is specialized in enzymology, protein chemistry, proteases in clinical biochemistry, cardiovascular disease and etc.

Dr. Shi is a professor of Department of Biochemistry and Molecular Biology, College of Medicine, National Cheng Kung University.

獎項

 

SANAR BIOTECH CORP.

© Copyright –SANAR BIOTECH CORP.